{"schema_version":"secwatch.filing_event.v1","accession":"0001437749-24-010505","form_type":"8-K","ticker":"BKYI","cik":"0001019034","company_name":"BIO KEY INTERNATIONAL INC","filed_at":"2024-04-02T23:59:59+00:00","discovered_at":"2026-05-14T18:03:16.907241+00:00","generated_at":"2026-06-04T03:15:48.093611+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"BIO-key reports preliminary 2023 revenue up 29% to $9.1M, net loss $(6.2M) after $2.8M inventory reserve","bullets":["2023 revenue $9.1M (+29% YoY); net loss $(6.2M) vs $(12.2M) in 2022; EPS $(11.45).","Q4'23 net loss $(4.1M) or $(5.54) per share, improved from $(6.7M) a year ago.","Took $2.8M non-cash reserve on slow-moving hardware inventory for Africa projects.","SG&A trimmed 22% to $7.3M; R&D down 26% to $2.4M.","Received $1.5M cash in Q1'24 for 2-year biometric license extension with existing customer."],"urls":{"canonical":"https://secwatch.observer/filing/0001437749-24-010505","json":"https://secwatch.observer/filing/0001437749-24-010505.json","markdown":"https://secwatch.observer/filing/0001437749-24-010505.md","text":"https://secwatch.observer/filing/0001437749-24-010505.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1019034/000143774924010505/0001437749-24-010505-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1019034/000143774924010505/bkyi20240401_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-04T03:15:48.093611+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"ca1ff0e5057a9650c31a6aaad339251c4c165528","claim":"BIO KEY INTERNATIONAL INC reported fourth quarter ended December 31, 2023 results: net income $(4.1M), EPS $(5.54) per share.","evidence_excerpt":"Likewise, in Q4’23 BIO-key reduced its net loss more than 40% to $(4.1M), or $(5.54) per share, from $(6.7M), or $(14.58) per share in 2023.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1019034/000143774924010505/0001437749-24-010505-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"fourth quarter ended December 31, 2023"},{"label":"Net income","value":"$(4.1M)"},{"label":"EPS","value":"$(5.54) per share"},{"label":"Result","value":"preliminary results"}],"fact_type":"earnings_release"},{"claim_id":"e7f7090712efeb08e5c76e9ea4c2b2bf48c368ff","claim":"BIO KEY INTERNATIONAL INC reported year ended December 31, 2023 results: revenue $9.1M, net income $(6.2M), EPS $(11.45) per share.","evidence_excerpt":"Exhibit 99.1 Identity and Access Management Software Provider BIO-key Preliminary 2023 Results: Operating Loss Trimmed Approx. $3.5M on Approx. 29% Revenue Growth to $9.1M; Investor Call Tomorrow at 10am ET Holmdel, NJ – April 1, 2024 – BIO-key® International, Inc. (Nasdaq: BKYI), an innovative provider of workforce and customer Identity and","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1019034/000143774924010505/0001437749-24-010505-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"year ended December 31, 2023"},{"label":"Revenue","value":"$9.1M"},{"label":"Net income","value":"$(6.2M)"},{"label":"EPS","value":"$(11.45) per share"},{"label":"Result","value":"preliminary results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}